We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- An Overview of Drug Discovery and Development
-
1. Rules and filters and their impact on success in chemical biology and drug discovery
- Dr. Christopher Lipinski
-
2. How medicines were discovered
- Dr. David C. Swinney
- Target Selection in Early Stage Drug Discovery
-
3. G-Protein coupled receptors in drug discovery
- Dr. Mark Wigglesworth
-
4. Enzymology in drug discovery 1
- Prof. Robert Copeland
-
5. Enzymology in drug discovery 2
- Prof. Robert Copeland
-
6. Inhibiting protein-protein interactions 1
- Dr. Adrian Whitty
-
7. Inhibiting protein-protein interactions 2
- Dr. Adrian Whitty
- Key Drug Discovery Challenges in Major Therapeutic Areas
-
8. Current trends in antiviral drug development
- Prof. Dr. Erik De Clercq
-
9. The challenge of developing drugs for neglected parasitic diseases
- Prof. James Mckerrow
-
10. Is there a role for academia in drug discovery
- Dr. Adrian J. Ivinson
-
11. Key drug discovery challenges in cardiovascular medicine
- Dr. Dan Swerdlow
- Dr. Michael V. Holmes
- Methods of Hit Identification
-
12. Fragment-based lead discovery
- Dr. Daniel A. Erlanson
- Medicinal Chemistry and SAR
-
13. Hit to lead
- Dr. Michael Rafferty
-
14. Prodrug strategies to overcome problems in drug therapy
- Prof. Jarkko Rautio
-
15. Deep ocean microorganisms yield mechanistically-novel anticancer agents
- Prof. William Fenical
- From Lead to Drug
-
16. Biomarkers in drug development: potential use and challenges
- Dr. Abdel-Bassett Halim
- Case Studies in Drug Discovery
-
17. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
19. Teixobactin kills pathogens without detectable resistance
- Prof. Kim Lewis
-
20. Discovery of schizophrenia drug targets from DISC1 mechanisms
- Prof. Atsushi Kamiya
- Archived Lectures *These may not cover the latest advances in the field
-
21. CNS-drug design
- Prof. Quentin Smith
-
22. Imatinib as a paradigm of targeted cancer therapies
- Prof. Brian Druker
-
23. New and emerging treatments for osteoporosis
- Dr. Michael Lewiecki
-
24. Prodrugs and drug delivery
- Prof. Jarkko Rautio
-
25. Where did drugs come from?
- Dr. David C. Swinney
Printable Handouts
Navigable Slide Index
- Introduction
- Take home messages (1)
- Outline
- Objective and challenges
- Definitions
- The cycle of drug discovery process
- Drug discovery uses available knowledge
- Part 2: how were medicines discovered?
- Chronology of drug discovery with some milestones
- Penicillin: serendipity
- Artemisinin: empirical, natural product
- Vemurafenib: target-based, structure enabled
- Daclatasvir: empirical, chemical optimization
- Definitions of drug discovery strategies
- How were new medicines discovered
- Conclusions from 2011 analysis
- Discovery strategies for first-in-class NMEs approved US FDA 1999-2017
- Discovery strategies for first-in-class NMEs 1999-2017: disease areas
- What have we learned from past successes?
- Spectrum of discovery strategies
- How do medicines work?
- Aspirin and Ibuprofen: one target, different uses
- Estrogen receptor modulators
- Communication of information
- Selectivity and specificity are important
- Mechanisms of first-in-class medicines
- Representative examples where physiologic context plays a role in specificity and efficacy
- Spectrum of discovery strategies
- Take home messages (2)
Topics Covered
- Drug discovery
- Drug discovery strategies
- Spectrum of discovery strategies
- Selectivity and specificity
- Mechanisms of first-in-class medicines
- Spectrum of discovery strategies
Talk Citation
Swinney, D.C. (2025, May 29). How medicines were discovered [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 1, 2025, from https://doi.org/10.69645/EZYH2032.Export Citation (RIS)
Publication History
- Published on May 29, 2025
Financial Disclosures
- There are no commercial/financial matters to disclose.
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, this is David Swinney.
I'm going to talk about
How Medicines Were Discovered.
I'm currently retired.
But before that, I was CEO of
the Institute for Rare and
Neglected Diseases Drug Discovery,
and prior to that, I had worked
at Roche for many years.
0:23
My take-home messages
for this talk are that
serendipity, knowledge,
and empiricism are
all utilized in the
discovery of new medicines.
First-in-class medicines are
discovered without a
blueprint as to how
efficacy, safety, and
specificity are to be achieved.
This is due to the fact that
there is an incomplete
understanding of
the molecular mechanisms of
action that will be needed.
Finally, physiological
context is
important and contributes to
the mechanism of specificity.
0:57
My job for the next 30
minutes or so is to
make sense of these
take-home messages.
I will do that through
the following outline
for this presentation.
In the first part,
I'll talk about drug
discovery objectives,
challenges, definitions,
and process.
In the second part,
I'll talk about
how medicines have been
discovered, past and present.
Finally, I'll conclude with
some thoughts that I have on
what has been learned
from past successes.
1:28
The objectives and challenges.
The objective of
drug discovery is to
identify therapeutics that are
effective for treating a
disease, and importantly,
that are safe—that
are tolerable.
The challenges are significant,
and probably the most
significant challenge is that
the failure rate is very high.
This leads to a high cost.
The reasons for this
failure rate are many and
they include trying to identify
a good starting point and
strategy for the discovery,
it's very difficult
to predict safety,
and that translation of
molecular information to
reliable knowledge is
challenging and difficult.